Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoingPhase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 population In target Phase 2 population: 100% of patients became eligible to transplant Pivotal Phase 2 first interim analysis expected in Q4 2026 BLA submission anticipated in 2028Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) ongoingBest-in-class dual allogeneic CAR-T cell product targeting CD20 & CD22 At current dose level, 88% ORR; 63% CR rate after 2+ prior lines of therapy 93% of subjects had prior CD19 CAR-T Low-dose IL-2 cohort to be included in; Full Phase 1 dataset expected in Q4 2026PartnershipsServier (through Allogene): Pivotal randomized Phase 2 ALPHA3 trial with cema-cel in 1L consolidation in LBCL: interim futility analysis evaluating MRD clearance and early safety...

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) — Diversified Royalty Corp. (TSX: DIV, DIV.DB.A and DIV.DB.B) (the “Corporation” or “DIV”) is pleased to announce its financial results for the three months (“Q4 2025”) and year ended December 31, 2025. HighlightsThe weighted average organic royalty growth1 of DIV’s diversified royalty portfolio was 3.0% in Q4 2025 and 4.1% for the year ended December 31, 2025, compared to 5.2% for the three months ended December 31, 2024 (“Q4 2024”) and 4.6% for the year ended December 31, 2024. The weighted average organic royalty growth1 on a constant currency basis was 3.0% in Q4 2025 and 3.8% for the year ended December 31, 2025, compared to 4.8% for Q4 2024 and 4.3% for the year ended December 31, 2024. Revenue was $19.1 million in Q4 2025 and $70.8 million for the year ended...

(Dollar amounts are in thousands, in Canadian currency unless otherwise specified) GUELPH, Ontario, March 19, 2026 (GLOBE NEWSWIRE) — Hammond Power Solutions Inc. (“HPS” or the “Company”) (TSX: HPS.A) a leading manufacturer of dry-type transformers, power quality products and related magnetics, today announced its financial results for the fourth quarter 2025. QUARTERLY HIGHLIGHTS:Record annual sales of $898 million, a 13.9% increase versus 2024; Quarterly adjusted EBITDA of $38.7 million, or 13.5% of sales; Record annual adjusted EBITDA of $133.3 million, or 14.8% of sales; Quarterly adjusted earnings per share of $1.98. Earnings per share of $1.28; Annual adjusted earnings per share of $6.81. Earnings per share of $6.07; Backlog is 122% higher than Q4 2024“HPS delivered a strong finish to 2025, with fourth quarter sales...

Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b long-term extension study which continues to support the favorable safety and tolerability profile of tegoprubart Tegoprubart granted Orphan Drug designation by the FDA for the prevention of allograft rejection in liver transplantation IRVINE, Calif., March 19, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2025 operating and financial results and reviewed recent business highlights. “Over the past year, Eledon has made significant progress advancing tegoprubart, our anti-CD40L antibody, as a potential next-generation immunosuppressive therapy across multiple...

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) — Glacier Media Inc. (TSX: GVC) (“Glacier” or the “Company”) reported revenue and earnings for the year ended December 31, 2025. Summary Results(thousands of dollars)  except share and per share amounts   2025     2024         Revenue $ 137,506   $ 141,946  EBITDA (1) $ 7,461   $ 9,712  EBITDA (1) margin   5.4%     6.8%  EBITDA (1) per share $ 0.06   $ 0.07  Capital expenditures $ 5,221   $ 3,848  Net income (loss) attributable to common shareholder $ 6,417   $ (24,442 )Net income (loss) attributable to common shareholder per share $ 0.05   $ (0.19 )       Weighted average shares outstanding, net   131,131,598     131,131,598         (1) EBITDA is considered a non-GAAP measure. Refer to “EBITDA Reconciliation” below for a reconciliation...

HAMILTON, BERMUDA, March 19, 2026 – DHT Holdings, Inc. (NYSE:DHT) (the “Company”) has filed its 2025 annual report on Form 20-F with the U.S. Securities and Exchange Commission (the “SEC”). The report and the audited financial statements are available on DHT’s website www.dhtankers.com and in the attachment included with this press release. Shareholders may request a hard copy of the audited financial statements free of charge by sending an e-mail to info@dhtankers.com.   About DHT Holdings, Inc.DHT is an independent crude oil tanker company. Our fleet trades internationally and consists of crude oil tankers in the VLCC segment. We operate through our integrated management companies in Monaco, Norway, Singapore, and India. You may recognize us by our renowned business approach as an experienced organization with focus on first rate operations...

— Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 — — Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC); additional updates expected throughout 2026 — — Appointed Jason Litten, M.D., as Chief Medical Officer to lead clinical development strategy — — $33.1 million in pro forma cash, cash equivalents, marketable securities and restricted cash as of December 31, 2025, including $18.5 million in net proceeds from underwritten offering of common stock in January 2026; expected to support operations into 1Q27– WESTLAKE VILLAGE, Calif., March 19, 2026 (GLOBE NEWSWIRE) — Genelux Corporation...

– Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally well tolerated in the 41 participants dosed as of March 18, 2026 – – Company anticipates dosing the first participant in the Phase 3 IMPACT DUCHENNE trial in April 2026; additional meetings planned with FDA in H1 2026 for guidance on a potential accelerated approval pathway for SGT-003 – – Friedreich’s Ataxia (SGT-212): First participant dosed in the Phase 1b FALCON trial; SGT-212 has been well tolerated with no treatment-related adverse events – – CPVT (SGT-501): Clinical sites activated for Phase 1b ARTEMIS first-in-human clinical trial evaluating SGT-501 for the treatment of catecholaminergic...

Alpha successfully returned to flight in March, as Firefly enters 2026 with new national security SciTec contracts.“Stairway to Seven” launching from Firefly’s Space Launch Complex 2 at Vandenberg Space Force Base in California on March 11, 2026. CEDAR PARK, Texas, March 19, 2026 (GLOBE NEWSWIRE) — Firefly Aerospace (Nasdaq: FLY), a market leading space and defense technology company, today issued financial results for the fourth quarter and fiscal year ended December 31, 2025. “2025 was a transformative year in Firefly’s history, as we more than doubled our annual revenue while executing across multiple launch, spacecraft, and ground programs and strengthening our portfolio of space exploration and national security space capabilities,” said Jason Kim, CEO of Firefly Aerospace. “Our laser...

— DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 — — Strong financial position with approximately $535 million in cash and cash equivalents as of February 28, 2026, expected to fund operations into Phase 3 development of DMR-001 — BOSTON, March 19, 2026 (GLOBE NEWSWIRE) — Damora Therapeutics, Inc. (formerly Galecto, Inc.) (“Damora” or the “Company”) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its operating and financial results for the year ended December 31, 2025, and recent corporate highlights. “At Damora Therapeutics, we strive to rapidly bring forward best-in-class medicines to dramatically improve the lives of patients with blood disorders....